Cargando…
TP53 Mutations in AML Patients Are Associated with Dismal Clinical Outcome Irrespective of Frontline Induction Regimen and Allogeneic Hematopoietic Cell Transplantation
SIMPLE SUMMARY: TP53 mutations are adverse-risk genetic aberrations in acute myeloid leukemia (AML). The optimal treatment approach in patients with TP53-mutated (TP53(MUT)) AML remains unclear. We aimed to evaluate the prognostic implications of different frontline treatment strategies and transpla...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296444/ https://www.ncbi.nlm.nih.gov/pubmed/37370821 http://dx.doi.org/10.3390/cancers15123210 |